Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dipicolinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.94 |
| ▸ | TSHR | P16473 | 2/20 | 0.94 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipicolinic Acid SCHEMBL890374 | 1.00 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL890375 | 1.00 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL720696 | 0.97 | KDM4E (1.00) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL34595 | 0.97 | KDM4E (1.00) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL6561776 | 0.94 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL3732330 | 0.94 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL11294102 | 0.94 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL6556692 | 0.94 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL9659122 | 0.94 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL15659942 | 0.94 | KDM4E (0.94) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117181020-A | Method for preparing nanofiltration membrane and nanofiltration membrane prepared by same | 沃顿科技股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-112062949-B | Semi-aromatic polyamino acid, semi-aromatic polyamino acid-based bone repair material and preparation thereof | 中鼎凯瑞科技成都有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-112546296-B | Composite bone repair material with light display effect and self-positioning function and preparation method thereof | 中鼎凯瑞科技成都有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-112546296-A | Composite bone repair material with light display effect and self-positioning function and preparation method thereof | 中鼎凯瑞科技成都有限公司 | 2021-03-26 | — | — | CN | claimed |
| CN-112062949-A | Semi-aromatic polyamino acid, semi-aromatic polyamino acid-based bone repair material and preparation thereof | 中鼎凯瑞科技成都有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-10828608-B2 | Semipermeable membrane and preparation method thereof | ZHEJIANG UNIVERSITY (CN) | 2020-11-10 | — | — | US | claimed |
| US-20190282967-A1 | SEMIPERMEABLE MEMBRANE AND PREPARATION METHOD THEREOF | LORD CORPORATION | 2019-09-19 | — | — | US | claimed |
| EP-0227043-A2 | Composite semipermeable membrane and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-07-01 | — | — | EP | claimed |
| EP-3774787-B1 | A COMPOUND, A REACTION PRODUCT OF SAID COMPOUND AND PRODUCTION METHODS THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-08-20 | — | — | EP | disclosed |
| CN-119899082-A | Method for using nitrogen-oxygen ligand modified low-content ruthenium-based catalyst in acetylene hydrochlorination | 南京工业大学 | 2025-04-29 | — | — | CN | disclosed |
| EP-4518842-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119546288-A | Novel lipid-based small molecule integrin receptor-ligand agonist adjuvant carrier compositions, integrin agonist adjuvant pharmaceutical compositions thereof, and methods of making and using the same | 7山药物公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12109263-B2 | Integrin agonists or activating compounds and methods for making and using same | 7 HILLS PHARMA INC. | 2024-10-08 | — | — | US | disclosed |
| CN-118325324-A | Composite material for high-heat-resistance outdoor tent and preparation method thereof | 仪征市祥生复合材料有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-0022827-A1 | REVERSE OSMOSIS MEMBRANE | Midwest Research Institute (US) | 1981-01-28 | — | — | EP | disclosed |
| EP-0015149-A1 | Interfacially synthesized reverse osmosis membrane, process for the preparation thereof and its use in a process for removing solute from solute-containing water | FilmTec Corporation (US) | 1980-09-03 | — | — | EP | disclosed |
| EP-0014054-A1 | Process for the production of a reverse osmosis membrane, reverse osmosis membrane thus produced, and use of such membrane in a desalination process | Midwest Research Institute (US) | 1980-08-06 | — | — | EP | disclosed |
| WO-1980001464-A1 | REVERSE OSMOSIS MEMBRANE | MIDWEST RESEARCH INST (US) | 1980-07-24 | — | — | WO | disclosed |
| US-4002563-A | REVERSE OSMOSIS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE INTERIOR (US) | 1977-01-11 | — | — | US | disclosed |
| US-3935172-A | REVERSE OSMOSIS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE INTERIOR (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12109263-B2 | Integrin agonists or activating compounds and methods for making and using same | ICOS, CD47, CD274 | CA2 2517/4885KDM4E 1595/4885ALOX15 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.